Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial
177Lu-PNT2002 met its primary endpoint of radiographic progression-free survival (rPFS) in the pivotal Phase III SPLASH trial (9.5 months vs 6.0 months, HR 0.71), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor…
